Digoxin remains useful in the management of chronic heart failure

Medical Clinics of North America

Volumn 87, Issue 2, 2003, Pages 317-337

  Dec, G William ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CARDIAC GLYCOSIDE; COLESTYRAMINE; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; FLECAINIDE; INOTROPIC AGENT; PROPAFENONE; QUINIDINE; SPIRONOLACTONE; VERAPAMIL;

CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; EXERCISE TOLERANCE; HEART FAILURE; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTHYROIDISM; OUTPATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

EID: 0037350868     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(02)00172-4     Document Type: Review

References (64)

1. Withering W. An account of the foxglove and some of its medical uses, with practical remarks on dropsy, and other diseases. In: Willius FA, Keys TE, editors. Classics of cardiology. New York: Dover Publications Inc.; 1941. Volume 1. p. 231-52.
2. Kelly RA, Smith TW. Pharmacological treatment of heart failure. In: Goodman and Gilman's the pharmacological basis of therapeutics, 9th edition. New York: McGraw-Hill; 1996. p. 809-38.
3. Skou JC. The Na, K pump. In: Fleischer S, Fleischer B, editors. Methods in enzymology. San Diego, Calif: Academic Press; 1988. Volume 156. p. 1-28.
4. Shull GE, Greeb J, Lingrel JB. Molecular cloning of three distinct forms of the Na+, K+ ATPase α-subunit from rat brain. Biochemistry 1986;25:8125-9.
5. Hassenfuss G, Mulieri LA, Allen PD, Just H, Alpert NR. Influence of isoproterenol and ouabain on excitation-contraction coupling, cross-bridge function, and energetics in failing human myocardium. Circulation 1996;94:3155-60.
6. Smith TW. Digitalis. Mechanisms of action and clinical uses. N Engl J Med 1988;318:358-365.
7. Im WB, Lee CO. Quantitative relation of twitch and tonic tensions to intracellular Na+ activity in cardiac Purkinje fibers. Am J Physiol 1984;247:C478.
8. Allen PD, Schmidt TA, Marsh JD, Kjeldsen K. Na, K-ATPase expression in normal and failing human left ventricle. Basic Res Cardiol 1992;87:87-92.
9. Marban E, Tsien RW. Enhancement of cardiac calcium current during digitalis inotropy. Positive feedback regulation by intracellular calcium. J Physiol 1982;329:589-614.
10. Eisner DA, Lederer WJ. Does sodium pump inhibition produce the positive inotropic effects of strophanthidin in mammalian cardiac muscle. J Physiol 1979;294:279-301.
11. McGarry SJ, Williams AJ. Digoxin activates sarcoplamic reticulum Ca2+ release channels. A possible role in cardiac inotropy. Br J Pharmacol 1993;108:1043-50.
12. Kim D, Cragoe EJ, Smith TW. Relations among sodium pump inhibition, Na-Ca and Na-H exchange activation, and Ca-H interaction in cultured chick heart cells. Circ Res 1987;60:185-93.
13. Santana LF, Gomez AM, Lederer WJ. Ca2+ flux through promiscuous cardiac Na+ channels: slip-mode conductance. Science 1998;279:1027-33.
14. Wang W, Chen JS, Sucker IH. Carotid sinus baroreceptor sensitivity in experimental heart failure. Circulation 1990;81:1959-66.
15. Alicandri C, Fariello R, Boni E, et al. Captopril versus digoxin in mild to moderate chronic heart failure. A crossover study. J Cardiovasc Pharmacol 1987;9:S61-7.
16. Kaye DM, Lambert GW, Lefkovits J, et al. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardilol 1994;23:570-8.
17. Krum H, Bigger JT, Goldsmith RL, Packer M. Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure. J Am Coll Cardiol 1995;25:289-94.
18. VanVeldhuisen DJ, deGriff PA, Remme WJ, Lie KI. Value of digoxin in heart failure and sinus rhythm: new features of an old drug? J Am Coll Cardiol 1996;28:813-9.
19. Gheorghiade M, Ferguson D. Digoxin. A neurohormonal modulator in heart failure? Circulation 1991;84:2181-6.
20. Newton GE, Tong JH, Schofield AM, Baines AD, Floras JS, Parker JD. Digoxin reduces cardiac sympathetic activity in severe heart failure. J Am Coll Cardiol 1996;28:155-61.
21. Friedman P. Therapeutic and toxic electrophysiologic effects of cardiac glycosides. In: Digitalis Glycosides. Orlando, FL: Grune and Stratton; 1985. p. 29.
22. Carlton RA, Miller PH, Grettinger JS. Effects of ouabain, atropine, and ouabain and atropine on A-V nodal conduction in man. Circ Res 1967;20:283-8.
23. Kaufman ES, Bosner MS, Bigger JT, et al. Effects of digoxin and enalapril on heart period variability and response to head-up tilt in normal subjects. Am J Cardiol 1993;72:95-9.
24. Hauptman PJ, Kelly RA. Digitalis. Circulation 1999;99:1265-70.
25. Mason DT, Braunwald E, Karash RB, Bullock FA. Studies on digitalis. X. Effects of ouabain on forearm vascular resistance and venous tone in normal subjects and in patients with heart failure. J Clin Invest 1964;43:532-43.
26. McMichael J, Sharpey-Schafer EP. Three actions of intravenous digoxin in man. Quar J Med 1944;19:459-71.
27. Ribner B, Plucinski DA, Hsieh AM, et al. Acute effects of digoxin on total systemic vascular resistance in congestive heart failure due to dilated cardiomyopathy. A hemodynamic-hormonal study. Am J Cardiol 1985;56:896-904.
28. Gheorghiade M, St Clair J, St Clair C, Beller GA. Hemodynamic effects of intravenous digoxin in patients with severe heart failure initially treated with diuretics and vasodilators. J Am Coll Cardiol 1987;9:849-57.
29. Cohn K, Selzer A, Kersh ES, et al. Variability of hemodynamic response to acute digitalization in chronic cardiac failure due to cardiomyopathy and coronary artery disease. Am J Cardiol 1975;31:461-8.
30. Gheorghiade M, Hall V, Lakier J, Goldstein S. Comparative hemodynamic and neurohumoral effects of intravenous captopril and digoxin and their combination patients with severe heart failure. J Am Coll Cardiol 1989;13:134-42.
31. Cantelli I, Vitolo A, Lombardi G, et al. Combined hemodynamic effects of digoxin and captopril in patients with congestive heart failure. Curr Ther Res 1984;36:323-7.
32. Ribner HS, Zucker MJ, Stisor C, et al. Vasodilators as first line therapy for congestive heart failure. A comparative hemodynamic study of hydralazine, digoxin, and their combination. Am Heart J 1983;106:308-15.
33. Cantelli I, Pavesi PC, Rarchi C, et al. Acute hemodynamic effects of combined therapy with digoxin and nifedipine in patients with chronic heart failure. Am Heart J 1983;106:308-15.
34. Raabe DS. Combination therapy with digoxin and nitroglycerin in heart failure complicating acute myocardial infarction. Am J Cardiol 1979:43:990-4.
35. Bonelli J, Jancuska M. Comparison of digoxin and dobutamine in patients with severe dilatative cardiomyopathy. Int J Clin Pharmacol Ther Toxicol 1989;27:120-5.
36. Tisdale JE, Gheorghiade M. Acute hemodynamic effects of digoxin alone or in combination with other vasoactive agents in patients with heart failure. Am J Cardiol 1992;69:34G-47G.
37. Tauke J, Goldstein S, Gheorghiade M. Digoxin for chronic heart failure. A review of the randomized controlled trials with special attention to the PROVED and RADIANCE trials. Prog Cardiovas Dis 1994;37:49-58.
38. Ferguson DW. Baroreceptor-mediated circulatory control in human heart failure. Heart Failure 1990:6:3-11.
39. Ferguson DW, Berg WJ, Saunders JS, et al. Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Circulation 1989;80:65-77.
40. Goldsmith SR, Simon AB, Miller E. Effect of digitalis on norepinephrine kinetics in congestive heart failure. J Am Coll Cardiol 1992;20:858-63.
41. Covit AB, Schaer GI, Sealy JE, et al. Suppression of the renin-angiotensin system by intravenous digoxin in chronic congestive heart failure. Am J Med 1983;75:445-7.
42. Dobbs SN, Kenyon WI, Dobbs RJ. Maintenance digoxin after an episode of heart failure. Placebo controlled trial in outpatients. Br Heart J 1977;1:749-52.
43. Fleg L, Gottlieb SH, Lakatta EG. Is digoxin really important in compensated heart failure? Am J Med 1982;73:244-50.
44. Taggart AJ, Johnson GD, McDevitt DG. Digoxin withdrawl after cardiac failure in patients with sinus rhythm. J Cardiovasc Pharm 1983;5:229-34.
45. Lee DCS, Johnson RA, Bingham JB, et al. Heart failure in outpatients. A randomized trial of digoxin versus placebo. N Engl J Med 1988;306:699-705.
46. Guyatt GH, Sullivan MJJ, Fallen EL, et al. A controlled trial of digoxin in congestive heart failure. Am J Cardiol 1998;61:371-5.
47. Haerer W, Bauer U, Hetzel M, Fehske J. Long-term effects of digoxin and diuretics in congestive heart failure. Results of a placebo-controlled randomized double-blind study. Circulation 1988;78(Suppl II):S53.
48. Captopril Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988;259:539-44.
49. German and Austrian Xamoterol Study Group. Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure. Lancet 1988;1:489-93.
50. DiBianco R, Shabetai R, Kostuk W, et al. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 1989;320:677-83.
51. Uretsky BF, Young JB, Shahidis J, et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure. Results of the PROVED trial. J Am Coll Cardiol 1993;22:955-62.
52. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med 1993;329:1-7.
53. Adams KF, Gheorghiade M, Uretsky BF, Young JB, Ahmed S, Tomasko L, et al. Patients with mild heart failure worsen during withdrawl from digoxin therapy. J Am Coll Cardiol 1997;30:42-8.
54. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
55. Smith TW. Digitalis glycosides. Orlando, FL: Grune and Stratton; 1985.
56. Halkin H, Sheiner LB, Peck CC, et al. Determinants of renal clearance of digoxin. Clin Parmacol Ther 1975;17:385-94.
57. Cogan JJ, Humphreys MH, Carlson CJ, et al. Acute vasodilator therapy increases renal clearance of digoxin in patients with congestive heart failure. Circulation 1981;64:973-6.
58. Cheng JWM, Charland SL, Shaw LM, Korbin S, Goldfarb S, Stanek EJ, et al. Is the volume of distribution of digoxin reduced in patients with renal dysfunction? Determining digoxin pharmacokinetics by fluorescence polarization immunoassay. Pharmacotherapy 1997;17:584-90.
59. Lewis RP. Clinical use of serum digoxin concentrations. Am J Cardiol 1992;69:97G-107G.
60. Gheorghiade M, Hall VB, Jacobsen G, Alam M, Rosman H, Goldstein S. Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting-enzyme inhibitors. Circulation 1995;92:1801-7.
61. Kelly RA, Smith TW. Recognition and management of digitalis toxicity. Am J Cardiol 1992;69:108G-19G.
62. Antman EM, Wegner TL, Butler VP, Haber E, Smith TW. Treatment of 150 cases of life-threatening digitalis intoxication: safety and efficacy results of an observational surveillance study. Circulation 1990;81:1744-52.
63. Adams KF, Baughman KL, Dec GW, et al. Heart Failure Society of America (HFSA) guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction-pharmacological approaches. J Card Fail 1999;5:357-82.
64. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 guidelines for the evaluation and management of heart failure). Circulation 2001;104:2996-3007.